share_log

Otonomy (NASDAQ:OTIC) Coverage Initiated at StockNews.com

Otonomy (NASDAQ:OTIC) Coverage Initiated at StockNews.com

Otonomy（納斯達克）覆蓋率於證券新聞網啟動
Financial News Live ·  2022/12/28 14:31

StockNews.com initiated coverage on shares of Otonomy (NASDAQ:OTIC – Get Rating) in a research report sent to investors on Saturday. The brokerage issued a hold rating on the biopharmaceutical company's stock.

證券新聞網啟動對股份的覆蓋 性 (納斯達克:奧迪 — 獲得評級) 在星期六發給投資者的研究報告中。該經紀公司對該生物製藥公司的股票發出了持有評級。

Separately, Piper Sandler cut shares of Otonomy from an overweight rating to a neutral rating and cut their price objective for the company from $3.00 to $0.50 in a report on Thursday, October 13th.

另外，派珀·桑德勒在 10 月 13 日（星期四）的一份報告中，將 Otonomy 的股票從超重評級削減為中性評級，並將公司的價格目標從 3.00 美元降至 0.50 美元。

Get
取得
Otonomy
音樂術
alerts:
警報：

Otonomy Price Performance

Otonomy 的價格表現

Shares of Otonomy stock opened at $0.07 on Friday. The firm has a fifty day moving average price of $0.11 and a 200 day moving average price of $0.66. Otonomy has a 1 year low of $0.06 and a 1 year high of $2.59. The stock has a market cap of $4.23 million, a PE ratio of -0.10 and a beta of 1.31.

本週五股票的開盤價為 0.07 美元。該公司的五十天移動平均價格為 0.11 美元，200 日移動平均價格為 0.66 美元。Otonomy 有 1 年的低點為 0.06 美元和 1 年的新高點為 2.59 美元。該股的市值為 423 萬美元，私募股比率為 -0.10，測試版為 1.31。

Institutional Trading of Otonomy

Otonomy 的機構交易

Several institutional investors have recently modified their holdings of OTIC. Two Sigma Investments LP grew its position in shares of Otonomy by 129.2% in the third quarter. Two Sigma Investments LP now owns 142,183 shares of the biopharmaceutical company's stock valued at $42,000 after purchasing an additional 80,153 shares during the period. Requisite Capital Management LLC acquired a new position in Otonomy during the third quarter worth about $44,000. State Street Corp boosted its position in Otonomy by 5.1% during the first quarter. State Street Corp now owns 182,239 shares of the biopharmaceutical company's stock worth $437,000 after acquiring an additional 8,839 shares during the last quarter. Lynx1 Capital Management LP boosted its position in Otonomy by 7,609.6% during the third quarter. Lynx1 Capital Management LP now owns 2,312,880 shares of the biopharmaceutical company's stock worth $682,000 after acquiring an additional 2,282,880 shares during the last quarter. Finally, Point72 Asset Management L.P. acquired a new position in Otonomy during the third quarter worth about $1,621,000. Institutional investors and hedge funds own 41.23% of the company's stock.
一些機構投資者最近修改了他們對奧迪的持有量。兩西格瑪投資 LP 在第三季度增長了其在 Otonomy 股份的地位 129.2％。兩個西格瑪投資 LP 現在擁有 142,183 股價值為 $42,000 的生物製藥公司股票在此期間額外購買 80,153 股後。必要資本管理有限責任公司在第三季度收購了 Otonomy 的新職位，價值約為 44,000 美元。在第一季度，州街公司將其在 Otonomy 的地位提高了 5.1％。州街公司現在擁有該生物製藥公司的 182,239 股股票，價值 437,000 美元，在上個季度額外收購 8,839 股股。Lynx1 資本管理有限公司在第三季度將其在 Otonomy 的地位提高了 7,609.6％。Lynx1 資本管理有限公司在上一季度額外收購 2,282,880 股股份後，擁有該生物製藥公司股票的 2,312,880 股，價值 682,000 美元。最後，Point72 資產管理有限責任公司在第三季度收購了 Otonomy 的新頭寸，價值約為 1,621,000 美元。機構投資者和對沖基金擁有公司股票的 41.23%。

Otonomy Company Profile

音之美公司簡介

(Get Rating)

(取得評分)

Otonomy, Inc, a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties.

Otonomy, Inc 是一家生物製藥公司，在美國開發神經病學治療藥物。該公司提供 OTO-313（N-甲基-D-天冬氨酸受體拮抗劑 gacyclidine）的可持續暴露配方，用於治療耳鳴的第二期臨床試驗；OTO-413（一種腦源性神經營養因子的持續暴露配方），用於修復耳蝸突觸病和聽力噪音困難的 IIA 期臨床試驗。

Featured Articles

特色文章

  • Get a free copy of the StockNews.com research report on Otonomy (OTIC)
  • 3 Industrial Stocks to Help Build Your 2023 Watchlist
  • The Institutions Choose CarMax Over Carvana, Should You?
  • Heatmap in Trading: How to Learn What Market Depth Hides
  • Micron Technology Sees Chip Recovery by the End of 2023
  • Three Healthcare Penny Stocks to Watch In The New Year
  • 免費獲取有關 OTONNOMY 的研究報告
  • 3 種工業股票可幫助建立您的 2023 觀察列表
  • 機構選擇 CarMax 而不是卡瓦娜，你應該嗎？
  • 交易中的熱圖：如何了解市場深度隱藏了什麼
  • 美光技術將在 2023 年底前恢復芯片
  • 三個醫療保健便士股在新的一年要關注

Receive News & Ratings for Otonomy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy and related companies with MarketBeat.com's FREE daily email newsletter.

接收 Otonomy 日報的最新消息和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件時事通訊接收 Otonomy 和相關公司的最新新聞和分析師評級的簡要每日摘要。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論